Improving the evaluation of new cancer treatments: Challenges and opportunities

Mace L. Rothenberg, David P. Carbone, David H. Johnson

Research output: Contribution to journalReview article

115 Scopus citations

Abstract

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalNature Reviews Cancer
Volume3
Issue number4
DOIs
StatePublished - Apr 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Improving the evaluation of new cancer treatments: Challenges and opportunities'. Together they form a unique fingerprint.

  • Cite this